Follow-up and OS among patients with DLBCL
Variable . | Median OS, mo . | 2-year OS, % . | 95% CI . |
|---|---|---|---|
| All patients, n = 126 | |||
| FOXP1 negative | 40.07 | 60 | 3.74-76.39 |
| FOXP1 weak positive | 49.28 | 58 | 0-103.81 |
| FOXP1 strong positive | 9.90 | 26 | 2.54-17.26 |
| Patients with non-GC phenotype and BCL2 expression, n = 70 | |||
| BCL2+FOXP1- | 28.39 | 50 | 7.31-49.46 |
| BCL2+FOXP1+ | 7.99 | 19.5 | 4.11-11.88 |
Variable . | Median OS, mo . | 2-year OS, % . | 95% CI . |
|---|---|---|---|
| All patients, n = 126 | |||
| FOXP1 negative | 40.07 | 60 | 3.74-76.39 |
| FOXP1 weak positive | 49.28 | 58 | 0-103.81 |
| FOXP1 strong positive | 9.90 | 26 | 2.54-17.26 |
| Patients with non-GC phenotype and BCL2 expression, n = 70 | |||
| BCL2+FOXP1- | 28.39 | 50 | 7.31-49.46 |
| BCL2+FOXP1+ | 7.99 | 19.5 | 4.11-11.88 |